docetaxel anhydrous has been researched along with isotretinoin in 3 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (isotretinoin) | Trials (isotretinoin) | Recent Studies (post-2010) (isotretinoin) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 4,064 | 506 | 1,216 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | isotretinoin (IC50) |
|---|---|---|---|
| Adenosine receptor A3 | Homo sapiens (human) | 4.169 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 4.169 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 6.612 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.462 | |
| Cellular retinoic acid-binding protein 1 | Gallus gallus (chicken) | 0.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.848 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 4.169 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 2.529 | |
| Olfactory receptor 51E2 | Homo sapiens (human) | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Candeloro, G; Di Orio, F; Guerriero, G; Piazze, J; Rea, S; Recchia, F | 1 |
1 review(s) available for docetaxel anhydrous and isotretinoin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for docetaxel anhydrous and isotretinoin
| Article | Year |
|---|---|
Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Killer Cells, Natural; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; T-Lymphocytes, Regulatory; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
1 other study(ies) available for docetaxel anhydrous and isotretinoin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |